SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. announced today that the company will be presenting at two upcoming investor conferences during which Mike Grey, president & chief executive officer of SGX Pharmaceuticals, will provide an overview of the Company’s oncology pipeline. The conference information is as follows:
A live webcast of the Lazard presentation will be available under the investor relations section of the Company’s website at http://www.sgxpharma.com. Replays of the presentation will be available for 90 days following the event. Please connect to the Company’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About SGX Pharmaceuticals
SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its FAST(TM) drug discovery platform, such as next generation BCR-ABL inhibitors being developed by SGX and in partnership with Novartis and MET tyrosine kinase inhibitors, including SGX523, and JAK2 inhibitors. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company’s various filings with the Securities and Exchange Commission.
CONTACT: Todd Myers, Chief Financial Officer of SGX Pharmaceuticals,
+1-858-558-4850; or Jason Spark, Media & Investor Relations of Porter
Novelli Life Sciences, +1-619-849-6005, for SGX Pharmaceuticals
Web site: http://www.sgxpharma.com/
